Chinese Medical E-ournals Database
Adv Search
中华妇幼临床医学杂志(电子版)

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2019, Vol. 15 ›› Issue (03): 268 -274. doi: 10.3877/cma.j.issn.1673-5250.2019.03.006

Special Issue: ；

Original Article

Predictive value of plate-to-lymphocyte ratio for International Federation of Obstetrics and Gynecology staging of ovarian cancer patients

Ying Tang1, Jun Li1, Huiquan Hu1,†(), Fan Xu1, Mingxing Chen2   

  1. 1. Department of Gynecology, Nanchong Central Hospital, Nanchong 637000, Sichuan Province, China
    2. North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
  • Received:2019-01-08 Revised:2019-05-04 Published:2019-06-01
  • Corresponding author: Huiquan Hu
  • About author:
    Corresponding author: Hu Huiquan, Email:
  • Supported by:
    Science & Technology Pillar Program by Science and Technology Department of Sichuan Province(2015JY0056); Project of Bureau of Science & Technology and Intellectual Property Nanchong City(17YFZJ0005, 18YFZJ0012)
HTML ( ) PDF ( )
Objective

To explore the predictive value of platelet-to-lymphocyte ratio (PLR) for International Federation of Obstetrics and Gynecology (FIGO) staging of ovarian cancer patients.

Methods

From January 2005 to January 2017, a total of 225 patients with primary ovarian cancer who were treated at Nanchong Central Hospital were selected into this study. According to different FIGO stagings, they were divided into early ovarian cancer group (n=85, FIGO stage Ⅰ-Ⅱ) and advanced ovarian cancer group (n=140, FIGO stage Ⅲ-Ⅳ). Wilcoxon rank sum test was used to statistically compare age, body mass index (BMI), white blood cell count, hemoglobin (Hb) level, PLR and neutrophil-to-lymphocyte ratio (NLR) between two groups. Chi-square test was used to statistically compare histopathological types, proportion of patients with ascites and proportion of serum CA125 level >35 U/mL. Then receiver operator characteristic (ROC) curve of PLR for predicting the FIGO staging of ovarian caner patients was drawn, and the area under ROC curve (ROC-AUC) was calculated. The optimal critical value of PLR for predicting the clincial staging of ovarian caner patients was obtained when the Youden index reaching the maximum value. And its sensitivity and specificity were calculated. This study met the requirements of the World Medical Association Declaration of Helsinki revised in 2013. Informed consent was obtairned from each participates.

Results

①There were significant differences in histopathological types, malignant ascites or not, serum CA125 level > 35 U/mL, PLR and NLR between two groups (χ2=16.897, 76.187, 11.817, -5.252, -3.790; P all<0.05), while there were no significant differences in age, BMI, Hb level and WBC count between two groups (P>0.05). ②Histopathological type (OR=2.460, 95%CI=1.246-4.856, P=0.009), malignant ascites (OR=6.649, 95%CI=3.437-12.862, P<0.001) and PLR (OR=1.005, 95%CI=1.001-1.009, P=0.027) were independent risk factors for ovarian cancer patients with different FIGO staging. ③ROC curve analysis showed that PLR for predicting FIGO staging of ovarian cancer patients was 0.709 (95%CI: 0.645-0.767, P<0.001). According to the principle of maximum Youden index, the optimal critical value for PLR to predict FIGO staging of ovarian cancer patients was 157.14, of which 134 patients with PLR > 157.14 and 91 patients with PLR≤157.14. At this time, the sensitivity was 72.9%, and the specificity was 63.5%.

Conclusions

PLR value can predict FIGO staging of ovarian cancer. When PLR>157.14, the FIGO staging of ovarian cancer patients is more likely to be advanced.

Key words: Ovarian neoplasms, Neoplasm staging, Inflammasomes, Plate to lymphocyte ratio, ROC curve, Women
表1 225例卵巢癌患者的一般临床资料
项目 结果 项目 结果
年龄[岁，M(P25～P75)] 50(18～89) 恶性腹水[例数(%)] ?
BMI[kg/m2，M(P25～P75)] 22.6(15.6～30.9) ? 是 134(59.6)
FIGO分期[例数(%)] ? ? 否 91(40.4)
? Ⅰ期 44(19.6) 白细胞计数[×109/L，M(P25～P75)] 7.2(3.3～16.5)
? Ⅱ期 41(18.2) 中性粒细胞计数[×109/L，M(P25～P75)] 4.5(1.7～13.1)
? Ⅲ期 122(54.2) 淋巴细胞计数[×109/L，M(P25～P75)] 1.3(0.3～2.8)
? Ⅳ期 18(8.0) Hb [g/L，M(P25～P75)] 116(50～161)
组织病理学类型[例数(%)] ? 血小板计数[×109/L，M(P25～P75)] 245(77～589)
? 浆液性 151(67.1) PLR [M(P25～P75)] 178(3～746)
? 非浆液性 74(32.9) NLR [M(P25～P75)] 3.4(1.1～17.1)
血清CA125[U/mL，M(P25～P75)] 160.6(1.4～5 672.6) ? ?
表2 2组卵巢癌患者的临床特征比较
组别 例数 组织病理学类型[例数(%)] 恶性腹水[例数(%)] 血清CA125 [例数(%)]
浆液性 非浆液性 是 否 >35 U/mL ≤35 U/mL
早期卵巢癌组 85 43(19.1) 42(18.7) 25(11.1) 60(26.7) 58(25.8) 27(12.0)
晚期卵巢癌组 140 108(48.0) 32(14.2) 109(48.4) 31(13.8) 122(54.2) 18(8.0)
检验值 ? χ2＝16.897 χ2＝76.187 χ2＝11.817
P值 ? <0.001 <0.001 0.001
组别 例数 中性粒细胞计数[×109/L，M(P25～P75)] 年龄[岁，M(P25～P75)] BMI [kg/m2，M(P25～P75)] 白细胞计数[×109/L，M(P25～P75)]
早期卵巢癌 85 4.1(203.0～11.0) 50(18～89) 22.6(15.6～30.9) 7.2(3.6～16.5)
晚期卵巢癌 140 4.8(1.7～13.1) 50(1～80) 23.4(16.5～31.2) 7.5(3.3～16.2)
检验值 ? Z＝—1.966 Z＝—0.879 Z＝—1.799 Z＝—1.633
P值 ? 0.049 0.380 0.075 0.102
组别 例数 Hb [g/L，M(P25～P75)] PLR[M(P25～P75)] NLR[M(P25～P75)] 淋巴细胞计数[×109/L，M(P25～P75)]
早期卵巢癌 85 114.0(50.0～143.0) 145.0(10.4～550.0) 2.6(1.1～12.1) 1.4(0.6～2.5)
晚期卵巢癌 140 116.5(61.0～161.0) 215.9(2.9～746.3) 4.2(1.2～17.1) 1.2(0.3～2.8)
检验值 ? Z＝—0.076 Z＝—5.252 Z＝—3.790 Z＝—4.004
P值 ? 0.939 <0.001 <0.001 <0.001
表3 卵巢癌患者FIGO分期影响因素的多因素非条件logistic回归分析变量含义及赋值情况
自变量/因变量 变量名 赋值
FIGO分期 y FIGO 2014年手术-病理分期
组织病理学类型 x1 x1＝0表示除浆液性卵巢癌外的其他组织病理学类型，x1＝1表示浆液性卵巢癌
是否合并恶性腹水 x2 x2＝0表示未合并恶性腹水，x2＝1表示合并恶性腹水
血清CA125水平 x3 x3＝0表示血清CA125水平<35 U/mL，x3＝1表示血清CA125水平≥35 U/mL
PLR x4 x4表示实际PLR
NLR x5 x5表示实际NLR
表4 卵巢癌患者FIGO分期影响因素的多因素非条件logistic回归分析结果
影响因素 B SE Wald值 P值 OR值 OR值95%CI
常数项 －2.753 0.519 28.137 <0.001 0.064 —
组织病理学类型 0.900 0.347 6.728 0.009 2.460 1.246～4.856
是否合并恶性腹水 1.894 0.337 31.667 <0.001 6.649 3.437～12.862
血清CA125水平 0.781 0.404 3.731 0.053 2.183 0.989～4.819
NLR 0.023 0.084 0.074 0.786 1.023 0.868～1.206
PLR 0.005 0.002 4.900 0.027 1.005 1.001～1.009
图1 PLR预测卵巢癌患者FIGO分期的ROC曲线
[1]
Ahmed N, Abubaker K, Findlay JK. Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets[J]. Mol Aspects Med, 2014, 39: 110-125.
[2]
Teng Z Han R, Huang X, et al.Increase of incidence and mortality of ovarian cancer during 2003-2012 in Jiangsu Province, China[J]. Front Public Health, 2016, 4: 146.
[3]
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296.
[4]
Morgan RJ Jr, Armstrong DK, Alvarez RD, et al. Ovarian cancer, version 1. 2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163.
[5]
Daly MB, Pilarski R2, Berry M, et al.NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2. 2017[J]. J Natl Compr Canc Netw, 2017, 15(1): 9-20.
[6]
Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline[J]. Gynecol Oncol, 2016, 143(1): 3-15.
[7]
Timmermans M, van der Aa MA, Lalisang RI, et al. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival inpatients with advanced ovarian cancer[J]. Gynecol Oncol, 2018, 150(3): 446-450
[8]
Elinav E, Nowarski R, Thaiss CA, et al. Inflammation induced cancer: crosstalk between tumours, immune cells and microorganisms[J]. Nat Rev Cancer, 2013, 13(11): 759-771.
[9]
Ceran MU, Tasdemir U, Colak E, et al. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? A survival analysis[J]. J Ovarian Res, 2019, 12(1): 16.
[10]
Zhang WW, Liu KJ, Hu GL, et al. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients[J]. Tumour Biol, 2015, 36(11): 8831-8837.
[11]
Ma XM, Sun X, Yang GW, et al. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a Meta-analysis[J]. Climacteric, 2017, 20(5): 448-455.
[12]
Zhu Y, Zhou S, Liu Y, et al. Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant Meta-analysis and systematic review[J]. BMC Cancer, 2018, 18(1): 443.
[13]
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? [J]. Lancet, 2001, 357(9255): 539-545.
[14]
李秋丽，张月香. 血小板增多症在卵巢癌中的研究进展[J]. 现代妇产科进展，2014, 23(10): 840-841.
[15]
Rao AK, Rao DA. Platelets signal and tumors take off[J]. Blood, 2012, 120(24): 4667-4668.
[16]
Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer[J]. N Engl J Med, 2012, 366(7): 610-618.
[17]
唐英，徐凡，罗祥力，等. 血小板/淋巴细胞计数比对卵巢癌临床预测价值的研究进展[J]. 西部医学，2017, 29(5): 725-728.
[18]
Fu BH, Fu ZZ, Meng W, et al. Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients[J]. Tumour Biol, 2015, 36(8): 6477-6483.
[19]
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting[J]. Immunity, 2004, 21(2): 137-148.
[20]
Rosenberg SA. Progress in human tumour immunology and immunotherapy[J]. Nature, 2001, 411(6835): 380-384.
[21]
Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma[J]. Br J Cancer, 2000, 83(2): 196-203.
[22]
Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF[J]. Blood, 2007, 110(2): 624-631.
[23]
刘艳，朱美琪，钱志红. 卵巢良恶性肿瘤患者血浆sIL-2R，IL-6及T细胞亚群变化研究[J]. 苏州医学院学报，2000, 20(1): 25-27.
[24]
Chen L, Zhang F, Sheng XG, et al. Decreased pretreatment lymphocyte/monocyte ratio is associated with poor prognosis in stage Ⅰb1-Ⅱa cervical cancer patients who undergo radical surgery[J]. Onco Targets Ther, 2015, 8: 1355-1362.
[25]
Ceran MU, Tasdemir U, Colak E, et al. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? A survival analysis[J]. J Ovarian Res, 2019, 12(1): 16.
[26]
Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis[J]. Cancer Res, 2012, 72(9): 2162-2171.
[27]
Wang H, Franco F, Ho PC, et al. Metabolic regulation of Tregs in cancer: opportunities for immunotherapy[J]. Trends Cancer, 2017, 3(8): 583-592.
[28]
Yigit R, Massuger LF, Figdor CG, et al. Ovarian cancer creates a suppressive mic roenvironment to escape immune elimination[J]. Gynecol Oncol, 2010, 117(2): 366-372.
[29]
Kuhn W, Pache L, Schmalfeldt B, et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO Ⅲ) after radical surgery and platinum-based chemotherapy[J]. Gynecol Oncol, 1994, 55(3): 401-409.
[30]
Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage Ⅲ ovarian cancer.[J]. Gynecologic Oncol, 2000, 77(2): 258-263.
[31]
Wimberger P, Wehling M, Lehmann N, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage Ⅳ disease[J]. Ann Surg Oncol, 2010, 17(6): 1642-1648.
[32]
Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.[J]. Int J Gynecol Pathol, 2004, 23(1): 29-34.
[33]
Medeiros LR, Rosa DD, Bozzetti MC, et al. Laparoscopy versus laparotomy for FIGO stage Ⅰ ovarian cancer[M]. New York: The Cochrane Library, 2005.
[34]
Kristensen GB, Vergote I, Stuart G, et al. First-line treatment of ovarian cancer FIGO stages Ⅱb-Ⅳ with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin[J]. Int J Gynecol Cancer, 2010, 13(s2): 172-177.
[35]
Lambert HE, Berry RJ. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages Ⅲ and Ⅳ): report from the North Thames Cooperative Group [J]. Br Med J, 1985, 290(6472): 889-893.
[36]
王鑫，张虹. 术前NLR和PLR对上皮性卵巢癌患者预后的评估价值[J]. 现代妇产科进展，2016, 25(6)：433-436.
[37]
唐英，李均，徐凡，等. 单核细胞与淋巴细胞比值及其与上皮性卵巢癌患者预后的关系 [J/CD] . 中华妇幼临床医学杂志(电子版)，2017，13(5): 532-538.
[38]
王刚，陈扬平. 晚期卵巢癌腹腔镜下肿瘤细胞减灭术的临床相关问题 [J/CD] . 中华妇幼临床医学杂志(电子版), 2016, 12(4): 373-378.
[39]
Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages ⅡA-Ⅳ: analysis of the OVCAD data.[J]. Int J Gynecol Cancer, 2012, 22(3): 380-385.
[40]
Grabowski J P, Harter P, Buhrmann C, et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO Ⅰ-ⅢA after sub-standard initial surgery[J]. Surg Oncol, 2012, 21(1): 31-35.
[1] Jingyu Qian, Mingming Zheng. Interpretation of the Italian guidelines on non-invasive and invasive prenatal diagnosis：executive summary of recommendations for practice the Italian Society for Obstetrics and Gynecology（SIGO）[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 486-492.
[2] Xialin Li, Fang He. Risk assessment and early warning system for postpartum hemorrhage[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 498-503.
[3] Ziyang Liu, Jianjian Cui, Yin Zhao. Current research status on obstetric disseminated intravascular coagulation and its scoring system[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 511-518.
[4] Fanying Zeng, Jie Ruan, Xinghui Liu, Guolin He. Current status of perinatal medicine advances under the new reproductive situation and coping strategies in prenatal care[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 519-524.
[5] Xiaofei Li, Hongli Liu, Qiuling Shi, Jing Tian, Li Li, Hongbo Qi, Xin Luo. A prospective randomized controlled study of low intensity focused ultrasound uterine involution treatment for prevention and treatment of postpartum hemorrhage in natural childbirth women[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 534-539.
[6] Rong Huang, Ziyu Liang, Wenjin Qi. Expression and significance of NLRP3 inflammasome in serum of pregnant women with premature rupture of membranes[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 540-548.
[7] Xia He, Rong Huang, Wenjin Qi. High-throughput sequencing study on the abundance of placenta and fetal membrane flora in pregnant women with premature rupture of membranes[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 549-555.
[8] Jiangyan Xie, Yafei Wang, Fang He. Pregnancy complicated with thrombotic thrombocytopenic purpura：two cases report and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 556-563.
[9] Xiaoyan Han, Hua Yang. Relationship between low level of serum placental growth factor in the second trimester pregnancy women and adverse fetal prognosis[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(04): 398-402.
[10] Jiali Du, Rui Bao, Chunhong Qiao, Wei Han. Construction of a prediction model for adverse pregnancy outcomes after emergency cervical cerclage in pregnant women with cervical incompetence during the second trimester[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(04): 403-409.
[11] Jinhan Yao, Weina Wang, Yuquan Zhang. Current research status on prognosis of patients with pregnancy-related deep vein thrombosis[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(04): 367-373.
[12] Tingting Xu, Yongchi Zhan, Xiaodong Wang, Xiaodong Wang. Perinatal outcomes of fetomaternal hemorrhage syndrome pregnant women with sinusoidal fetal heart tracing[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(04): 382-389.
[13] Juan Tan, Jianxin Tan, Binbin Shao, Yan Wang, Zhengfeng Xu. Current research status on non-invasive prenatal testing for fetal with single gene inheritance diseases[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(03): 245-250.
[14] Yue Zhao, Kun Tian, Zongming Zhang, Zhentian Guo, Limin Liu, Chong Zhang, Zhuo Liu. Predictive value of procalcitonin for incidence of acute severe cholecystitis in elderly patients[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 801-806.
[15] Xiaorong Peng, Wei Mo, Qin Li, Yaqin Wu, Lan Li. Knowledge, attitude and practice of venous thromboembolism prevention and influencing factors among pregnant women[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(03): 274-280.
Viewed
Full text


Abstract

Copyright © Chinese Medical Association, Chinese Medical Multimedia Press  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号